Clinical Trials Using Omacetaxine Mepesuccinate
Clinical trials are research studies that involve people. The clinical trials on this list are studying Omacetaxine Mepesuccinate. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Omacetaxine Mepesuccinate in Treating Patients with Intermediate-1 Risk or Higher Risk Myelodysplastic Syndrome That Has Not Responded to Chemotherapy Agents
This phase II trial studies how well omacetaxine mepesuccinate works in treating patients with intermediate-1 risk or higher risk myelodysplastic syndrome that has not responded to chemotherapy agents, such as decitabine or azacitidine. Omacetaxine mepesuccinate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may help control myelodysplastic syndrome.
Location: M D Anderson Cancer Center, Houston, Texas
Omacetaxine Mepesuccinate after Cytarabine and Daunorubicin Hydrochloride, Idarubicin, or Mitoxantrone Hydrochloride in Treating Older Patients with Acute Myeloid Leukemia in First Remission
This pilot clinical trial studies omacetaxine mepesuccinate after cytarabine and daunorubicin hydrochloride, idarubicin, or mitoxantrone hydrochloride in treating older patients with acute myeloid leukemia in first remission (a decrease in or disappearance of signs and symptoms of cancer). Drugs used in chemotherapy, such as omacetaxine mepesuccinate, cytarabine, daunorubicin hydrochloride, idarubicin, and mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving omacetaxine mepesuccinate after cytarabine and daunorubicin hydrochloride, idarubicin, or mitoxantrone hydrochloride may kill more cancer cells.
Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1 / Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a fixed-dose administration to patients with CP or AP CML who have failed 2 or more tyrosine kinase inhibitor (TKI) therapies.
Location: See Clinical Trials.gov